Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.02 USD | -1.91% | -4.78% | -23.35% |
Apr. 19 | Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement | MT |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Financials (USD)
Sales 2022 | 25.9M | Sales 2023 | 42.81M | Capitalization | 17.99M |
---|---|---|---|---|---|
Net income 2022 | -33M | Net income 2023 | -24M | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M | Net cash position 2023 | 26.37M | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | 48 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.57% |
Latest transcript on Pieris Pharmaceuticals, Inc.
1 day | -3.77% | ||
1 week | -3.10% | ||
Current month | -4.01% | ||
1 month | -21.07% | ||
3 months | -22.80% | ||
6 months | -45.96% | ||
Current year | -22.80% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 70 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 11.16 | -0.71% | 4 802 |
24-05-02 | 11.24 | -3.77% | 81,627 |
24-05-01 | 11.68 | -0.26% | 48,171 |
24-04-30 | 11.71 | 0.00% | 13,954 |
24-04-29 | 11.71 | -0.09% | 14,987 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-22.80% | 13.9M | |
-1.65% | 103B | |
+6.75% | 101B | |
+5.71% | 23.07B | |
-12.60% | 22.23B | |
-9.70% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- PIRS Stock